Mind Medicine (mindmed) . Subordinate Voting Shares Stock News

This article was originally published on Microdose and appears here with permission. MindMed ended its 2021 news cycle on a somewhat mehhh note.

Mind Medicine <> said it enrolled the first participants in its Session Monitoring System (SMS-01) study evaluating the passive collection of sensory data during…

Psychedelics biotech company MindMed (NASDAQ:MNMD) has enrolled the first subjects into its Session Monitoring System study. The company's Session Monitoring System is a technology platform that can c

Mind Medicine Inc (Sub Voting) (MNMD) shares closed 0.9% lower than its previous 52 week low, giving the company a market cap of $549M. The stock is currently down 12.3% year-to-date, down 57.1% over the past 12 months, and down 76.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 46.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Stephen Hurst Steps Down From MindMed's Board Of Directors Psychedelic-focused biotech company Mind Medicine Inc (NASDAQ: MNMD) announced on Friday that Stephen Hurst has resigned from his role as 

Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies wit

On Tuesday, Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ) reported the completion of its Phase 1 clinical trial of 18-MC, the company's non-hallucinogenic proprietary derivative of ibogaine,

Mind Medicine Inc (Sub Voting) (MNMD) shares closed 2.1% lower than its previous 52 week low, giving the company a market cap of $672M. The stock is currently down 51.5% year-to-date, down 51.6% over the past 12 months, and down 66.3% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 31.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for investors and entrepreneurs alike. If 2020 was the year

MindMed Announces Management Shake-Ups Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a psychedelic-based biotech company, announced Wednesday that Bradford Cross, its chief technology offic

The plans to test LSD in anxiety patients in a clinical study have been stopped in their tracks as the US Food and Drug Administration (FDA) has halted the process for unclear reasons. According to Reuters, the US FDA has put a clinical hold on Mind Medicine Incs application to start testing psychedelic drugs, such [] The post Another blow to the psychedelic industrys attempts to use LSD for therapeutic purposes appeared first on Canex .

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as 1.44 and last traded at 1.47, with a volume of 7451 shares changing hands. The stock had previously closed at 1.63. Separately, Zacks Investment Research cut Mind Medicine (MindMed) from a hold [] The post Mind Medicine (MindMed) (NASDAQ:MNMD) Sets New 12-Month Low at $1.44 appeared first on ETF Daily News .

MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, announced on